Loquen XR 400 mg tablete s produljenim oslobađanjem
Name | Loquen XR 400 mg tablete s produljenim oslobađanjem |
---|---|
Marketing Authorisation Number | HR-H-162034716 |
Active Substance | kvetiapinfumarat |
Composition | svaka tableta sadrži 400 mg kvetiapina u obliku kvetiapinfumarata |
Pharmaceutical Form | tableta s produljenim oslobađanjem |
Packaging [MA Number for Packaging] | 10 tableta u blisteru, u kutiji [HR-H-162034716-01] 20 tableta u blisteru, u kutiji [HR-H-162034716-02] 30 tableta u blisteru, u kutiji [HR-H-162034716-03] 50 tableta u blisteru, u kutiji [HR-H-162034716-04] 50 tableta u blisteru s jediničnom dozom, u kutiji [HR-H-162034716-05] 56 tableta u blisteru, u kutiji [HR-H-162034716-06] 60 tableta u blisteru, u kutiji [HR-H-162034716-07] 90 tableta u blisteru, u kutiji [HR-H-162034716-08] 100 tableta u blisteru, u kutiji [HR-H-162034716-09] 60 tableta u bočici, u kutiji [HR-H-162034716-10] 100 tableta u blisteru s jediničnom dozom, u kutiji [HR-H-162034716-11] |
Manufacturer | Teva Gyogyszergyar Zrt., Debrecen, Mađarska
Pharmachemie B.V., Haarlem, Nizozemska Teva Czech Industries s.r.o., Opava-Komarov, Češka Teva Operations Poland Sp. z o.o., Krakow, Poljska Teva Pharma S.L.U., Zaragoza, Španjolska Merckle GmbH, Blaubeuren, Baden-Wuerttemberg, Njemačka Adamed Sp. z o.o., Czosnow, Poljska |
Marketing Authorisation Holder | Pliva Hrvatska d.o.o., Prilaz baruna Filipovića 25, Zagreb, Hrvatska |
Marketing Authorisation Date | 08.05.2019 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/18-02/165 |
Registration Number | 381-12-01/38-19-03 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | N05AH04 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |
Public Assessment Report | download |
Educational materials for healthcare professionals |
Podsjetnik o važnosti nadziranja, verzija 3 |